Q4 2013 ACADIA Pharmaceuticals Earnings Release – After Market Close
moreView todays social media effects on ACADView the latest stocks trending across Twitter. Click to view dashboardSee who ACADIA is hiring next, click here to view […]
ACAD
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
[Business Wire] – ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today anno moreView todays social media effects on ACADView the latest stocks trending across Twitter. Click to view dashboardSee who ACADIA is hiring next, click here to view […]
Understanding The Investment Opportunity In Developmental Biotechnology
[at Seeking Alpha] – Editors’ Note: This article discusses micro-cap stocks. Please be aware of the risks associated with these stocks If it were easy to find the next biotech hot stock everyone would be a millionaire… … moreView todays social media effects on ACADView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: Acadia’s Value Heavily Dependent On Pimavanserin Data
[ACN Newswire] – By Jason Napodano, CFAWhen Acadia Pharmaceuticals (NASDAQ:ACAD) held its third quarter conference call on Nov 5, 2012 ( webcast link ) management noted that top-line data from the company’s phase 3 trial, … moreView todays social media effects on ACADView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: As ACAD Rises into Pimavanserin Data, ATM Use May Continue
[ACN Newswire] – By Jake KingAcadia Pharmaceuticals (NASDAQ:ACAD) announced its 3Q financial results Monday, reiterating the expectation for top-line pimavanserin data by the end of the month and reporting the first use … moreView todays social media effects on ACADView the latest stocks trending across Twitter. Click to view dashboard […]
